20054-45-9

Basic information

• Product Name: N-methyl-2-sulfanylbenzamide
• Synonyms: N-methyl-2-sulfanylbenzamide;BenzaMide, 2-Mercapto-N-Methyl-;2- Mercapto-N-MethyllbenzaMide;2-MERCAPTO-N-METHYL BENZAMIDE(RE-EXPORTWIDE B/E.NO:2513786 DT 08.09.2015)
• CAS NO: 20054-45-9
• Molecular Formula: C8H9NOS
• Molecular Weight: 167.231
• EINECS: 1592732-453-0
• Product Categories: Intermediate
• Mol File: 20054-45-9.mol
• Article Data: 13

Chemical Properties

• Melting Point: 94-96 °C
• Boiling Point: 326.2 °C at 760 mmHg
• Flash Point: 151.1 °C
• Appearance: /
• Density: 1.174
• Storage Temp.: 2-8°C
• PKA: 5.89±0.43(Predicted)
• CAS DataBase Reference: N-methyl-2-sulfanylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-2-sulfanylbenzamide(20054-45-9)
• EPA Substance Registry System: N-methyl-2-sulfanylbenzamide(20054-45-9)

Safety Data

• Hazardous Substances Data: 20054-45-9(Hazardous Substances Data)

Usage

Description

N-methyl-2-sulfanylbenzamide, also known as 2-mercapto-N-methyl-benzamide, is an intermediate compound used in the synthesis of axitinib (A794650), a potent tyrosine kinase inhibitor. It plays a crucial role in the development of cancer therapeutics due to its ability to inhibit specific enzymes involved in cancer cell growth and proliferation.

Uses

Used in Pharmaceutical Industry:
N-methyl-2-sulfanylbenzamide is used as an intermediate in the synthesis of axitinib, a tyrosine kinase inhibitor, for cancer therapy. Axitinib targets various cancer-related pathways, such as VEGFR, PDGFR, and c-Kit, thereby inhibiting angiogenesis and tumor growth. It is particularly effective in treating advanced renal cell carcinoma and other solid tumors.
Used in Cancer Therapy:
N-methyl-2-sulfanylbenzamide is used as a key component in the development of axitinib, which is employed as an anticancer agent. Axitinib has demonstrated efficacy in treating various types of cancer, including renal cell carcinoma, hepatocellular carcinoma, and non-small cell lung cancer. Its tyrosine kinase inhibitory properties contribute to its ability to disrupt cancer cell signaling and proliferation, making it a valuable tool in the fight against cancer.

Upstream product

• 2527-58-4 2,2'-dithiobis(N-methylbenzamide) 
• 2527-66-4 2-methyl-1,2-benzisothiazole-3(2H)-one 
• 593-51-1 methylamine hydrochloride 
• 4892-02-8 Methyl thiosalicylate 
• 54705-26-9 ortho-[(N-methyl)carbamoyl]phenyl benzyl sulfoxide 
• 19602-82-5 2,2'-dithiodibenzoic acid dichloride 
• 119-80-2 2,2'-dithiobenzoic acid 
• 872220-83-2 2-(4-methoxybenzylsulfinyl)-N-methylbenzamide 
• 872220-84-3 N-methyl-2-(4-(trifluoromethyl)benzylsulfinyl)benzamide 
• 1315275-16-1 (S)-2-(benzylsulfinyl)-N-methylbenzamide 
• 1315275-23-0 N-methyl-2-(4-methyl-1-phenylpentylsulfinyl)benzamide 
• 1531-80-2 2-(benzylthio)benzoic acid 
• 101093-83-8 2-(4-methoxy-benzylsulfanyl)-benzoic acid 
• 1050884-48-4 2-(4-trifluoromethyl-benzylsulfanyl)-benzoic acid 

Downstream Products

• 92963-22-9 2-(4-methoxy-phenyl)-3-methyl-2,3-dihydro-benzo[e][1,3]thiazin-4-one 
• 343869-24-9 2-(N-methylcarbamoyl)phenyl 2-methylphenyl sulfide 
• 343869-28-3 2-(N-methylcarbamoyl)phenyl 4-chlorophenyl sulfide 
• 343869-32-9 2-(N-methylcarbamoyl)phenyl 4-acetylphenyl sulfide 
• 343869-33-0 2-(N-methylcarbamoyl)phenyl 4-carboxy3henyl sulfide 
• 127905-49-1 2-(N-methylcarbamoyl)phenyl 2-methoxyphenyl sulfide 
• 135781-45-2 2-<2-(N-methylcarbamoyl)phenylthio>benzoic acid 
• 343869-27-2 2-(N-methylcarbamoyl)phenyl 4-methylphenyl sulfide 
• 343869-25-0 2-(N-methylcarbamoyl)phenyl 2-chlorophenyl sulfide 
• 127905-51-5 2-(N-methylcarbamoyl)phenyl 4-methoxyphenyl sulfide 
• 334632-65-4 N-methyl-2-(4-bromo-2-nitrophenylthio)benzamide 
• 252731-18-3 2-(N-methylcarbamoyl)phenyl 2-nitrophenyl sulfide 
• 100695-82-7 2-(N-methylcarbamoyl)phenyl 2-(methoxycarbonyl)phenyl sulfide 
• 343869-30-7 2-(N-methylcarbamoyl)phenyl 4-(methoxycarbonyl)phenyl sulfide 

Relevant articles and documents

Axitinib intermediate compound and preparation method thereof

The invention belongs to the field of pharmaceutical chemicals, and particularly relates to an axitinib intermediate compound and a preparation method thereof. The present invention provides a novel axitinib intermediate compound S-(2-(methylcarbamoyl) phenyl) dimethylthioformate, the invention also provides a preparation method thereof. The method comprises the following steps: dissolving 2-hydroxy-N-methylbenzamide in an organic solvent, and adding dimethylaminothioformyl chloride and a catalyst to obtain the S-(2-(methylcarbamoyl) phenyl) dimethylthioformate. The new intermediate compound can be used for preparing the axitinib important intermediate 2-sulfydryl-N-methylbenzamide, and the synthesis method provided by the invention is short in route, simple to operate and high in yield and purity of the obtained 2-sulfydryl-N-methylbenzamide, and is suitable for industrial production.

Safe, Scalable, Inexpensive, and Mild Nickel-Catalyzed Migita-Like C?S Cross-Couplings in Recyclable Water

A new approach to C?S couplings is reported that relies on nickel catalysis under mild conditions, enabled by micellar catalysis in recyclable water as the reaction medium. The protocol tolerates a wide range of heteroaromatic halides and thiols, including alkyl and heteroaryl thiols, leading to a variety of thioethers in good isolated yields. The method is scalable, results in low residual metal in the products, and is applicable to syntheses of targets in the pharmaceutical area. The procedure also features an associated low E Factor, suggesting a far more attractive entry than is otherwise currently available, especially those based on unsustainable loadings of Pd catalysts.

NOVEL ULK1 INHIBITORS AND METHODS USING SAME

In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.